Clinical Trials Logo

Pneumococcal Pneumonia clinical trials

View clinical trials related to Pneumococcal Pneumonia.

Filter by:
  • None
  • Page 1

NCT ID: NCT03851978 Completed - Clinical trials for Pneumococcal Pneumonia

Pharmacist Impact on Pneumococcal Polysaccharide Vaccination Rates in Patients With Diabetes in a Supermarket Pharmacy Chain

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

The goals of the study are to determine the pneumococcal polysaccharide vaccination rate in patients with diabetes before and after community pharmacist education and intervention. Assess barriers of receiving the pneumococcal polysaccharide vaccine in patients with diabetes after pharmacist education in a supermarket chain setting

NCT ID: NCT03619252 Completed - Multiple Myeloma Clinical Trials

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

Start date: July 1, 2018
Phase: Phase 4
Study type: Interventional

Multiple myeloma is an incurable blood cancer of plasma cells that occurs in older individuals. Novel agents (proteasome inhibitors, immunomodulatory agents) have substantially improved the overall response rates, progression-free survival and overall survival in patients with multiple myeloma. Patients with multiple myeloma are at high risk of developing life-threatening Streptococcus pneumoniae infections, while clinical efficacy and safety of conjugate pneumococcal vaccines in multiple myeloma patients receiving novel agents have not been studied before. The main aim of this study is to assess the clinical efficacy and safety of 13-valent pneumococcal conjugate vaccine in multiple myeloma patients treated with novel agents.

NCT ID: NCT03303976 Completed - Clinical trials for Pneumonia, Bacterial

Phase I to Test a New Pneumococcal Vaccine

Start date: September 7, 2017
Phase: Phase 1
Study type: Interventional

To obtain first-in-human data on a new candidate vaccine against Streptococcus pneumoniae in healthy adult and elderly volunteers. The study aims to assess the safety and immunogenicity of a bioconjugate investigational vaccine compared to the control group (Pneumovax23).

NCT ID: NCT02592486 Completed - Influenza Clinical Trials

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Start date: November 2015
Phase: Phase 4
Study type: Interventional

The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza vaccine and pneumococcal vaccine with that of separate administration.

NCT ID: NCT01444352 Completed - Clinical trials for Pneumococcal Infections

Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adult volunteers. Primary Objective: - To evaluate the safety and tolerability of an investigational pneumococcal vaccine. Observational Objective: - To evaluate the immunogenicity of an investigational Pneumococcal vaccine.

NCT ID: NCT01444339 Completed - Clinical trials for Pneumococcal Infections

Study of Two Investigational Pneumococcal Vaccines in Healthy Adults

Start date: February 2010
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the safety, tolerability, and immunogenicity of two investigational pneumococcal vaccines at three dose levels in healthy adults. Primary Objective: - To evaluate the safety and tolerability of two investigational pneumococcal vaccines. Observational Objective: - To evaluate the immunogenicity of the investigational pneumococcal vaccines.

NCT ID: NCT01444001 Completed - Clinical trials for Pneumococcal Infections

Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers

Start date: February 2007
Phase: Phase 1
Study type: Interventional

This study was designed to evaluate the safety, tolerability, and immunogenicity of three doses of an investigational pneumococcal vaccine in healthy adult volunteers. Primary Objective: - To evaluate the safety and tolerability of an investigational Pneumococcal vaccine.

NCT ID: NCT01402245 Completed - Clinical trials for Pneumococcal Pneumonia

Targeting of Immune Response After Pneumococcal Vaccination

PncHR
Start date: January 2005
Phase: Phase 4
Study type: Interventional

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

NCT ID: NCT01028326 Active, not recruiting - Clinical trials for Pneumococcal Pneumonia

PCV10 Reactogenicity and Immunogenicity Study - Malindi

PRISM
Start date: January 2010
Phase: Phase 4
Study type: Interventional

The World Health Organization has recommended that developing countries should incorporate pneumococcal conjugate vaccine (PCV) into their routine immunization schedules. The Kenya Ministry of Health anticipates introducing a new formulation of PCV, PCV10, into the routine childhood immunization schedule in 2010. In the areas of Kenya that have been designated to monitor the impact of vaccine, a catch-up campaign will be implemented to vaccinate children aged 12-59 months. PCV10 has been found to be safe and effective in infants. It is licensed for use in children up to 2 years of age, but its use as a primary series in children over age 12 months has not been evaluated. This study will assess the immunogenicity and reactogenicity of PCV10 first administered at an age of 12-59 months.